Complement and cardiovascular disease - The missing link in haemodialysis patients?

Nephron

Volumn 132, Issue 1, 2016, Pages 5-14

  Lines, Simon W ^a   Richardson, Victoria R ^b   Thomas, Bryn ^b   Dunn, Emma J ^c   Wright, Mark J ^c   Carter, Angela M ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cardiovascular disease; Complement; Haemodialysis; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; SC5B 9 PROTEIN; UNCLASSIFIED DRUG; ARTIFICIAL MEMBRANE; COMPLEMENT MEMBRANE ATTACK COMPLEX; SC5B-9 PROTEIN COMPLEX;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; ARTIFICIAL MEMBRANE; BLOOD; GENETICS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COMPLEMENT C3; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; VITAMIN E;

EID: 84953807023     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000442426     Document Type: Article

References (46)

1. van Greevenbroek MM, Jacobs M, van der Kallen CJ, Blaak EE, Jansen EH, Schalkwijk CG, Feskens EJ, Stehouwer CD: Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 2012; 154: 158-162.
2. Carter AM, Prasad UK, Grant PJ: Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis 2009; 203: 538-543.
3. Ajjan R, Grant PJ, Futers TS, Brown JM, Cymbalista CM, Boothby M, Carter AM: Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005; 94: 1048-1053.
4. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P: Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000; 21: 1081-1090.
5. Onat A, Uzunlar B, Hergenc G, Yazici M, Sari I, Uyarel H, Can G, Sansoy V: Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 2005; 108: 129-135.
6. Engstrom G, Hedblad B, Berglund G, Janzon L, Lindgarde F: Plasma levels of complement C3 is associated with development of hypertension: A longitudinal cohort study. J Hum Hypertens 2007; 21: 276-282.
7. Engstrom G, Hedblad B, Janzon L, Lindgarde F: Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: A population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007; 14: 392-397.
8. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, Kramer J, Fust G, Kleiber M, Romics L, Varga L: Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-389.
9. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P: Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-364.
10. Mellbin LG, Bjerre M, Thiel S, Hansen TK: Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: A report from the DIGAMI 2 trial. Diabetes Care 2012; 35: 911-917.
11. Chanard J, Lavaud S, Randoux C, Rieu P: New insights in dialysis membrane biocompatibility: Relevance of adsorption properties and heparin binding. Nephrol Dial Transplant 2003; 18: 252-257.
12. Deppisch R, Gohl H, Smeby L: Microdomain structure of polymeric surfaces - potential for improving blood treatment procedures. Nephrol Dial Transplant 1998; 13: 1354-1359.
13. Hauser AC, Derfler K, Stockenhuber F, Janata O, Balcke P: Generation of the membrane attack complex during haemodialysis: Impact of classical and alternative pathway components. Clin Sci (Lond) 1990; 79: 471-476.
14. Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1: 150-161.
15. Volanakis JE, Barnum SR, Giddens M, Galla JH: Renal filtration and catabolism of complement protein D. N Engl J Med 1985; 312: 395-399.
16. The Renal Association: UK Renal Registry: The Sixteenth Annual Report, 2013.
17. Omata M, Higuchi C, Demura R, Sanaka T, Nihei H: Reduction of neutrophil activation by vitamin E modified dialyzer membranes. Nephron 2000; 85: 221-231.
18. Pertosa G, Grandaliano G, Soccio M, Martino C, Gesualdo L, Schena FP: Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells. Kidney Int 2002; 62: 602-610.
19. Lines SW, Carter AM, Dunn EJ, Lindley EJ, Tattersall JE, Wright MJ: A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane. Nephrol Dial Transplant 2014; 29: 649-656.
20. Mollnes TE, Lea T, Harboe M, Tschopp J: Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985; 22: 183-195.
21. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 suppl 3):S112-S119.
22. Greenstein JD, Peake PW, Charlesworth JA: The kinetics and distribution of C9 and SC5b-9 in vivo: Effects of complement activation. Clin Exp Immunol 1995; 100: 40-46.
23. Podack ER, Muller-Eberhard HJ: SC5b-9 complex of complement: Formation of the dimeric membrane attack complex by removal of S-protein. J Immunol 1980; 124: 1779-1783.
24. Tschopp J, French LE: Clusterin: Modulation of complement function. Clin Exp Immunol 1994; 97(suppl 2):11-14.
25. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
26. Mares J, Richtrova P, Hricinova A, Tuma Z, Moravec J, Lysak D, Matejovic M: Proteomic profiling of blood-dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis-induced inflammatory response. Proteomics Clin Appl 2010; 4: 829-838.
27. Baumgartner-Parzer SM, Seyfert UT, Mannhalter C: Possible clinical effects of the interaction of hemodialysis membranes with adhesion proteins. Kidney Int 1995; 47: 1115-1120.
28. Mares J, Thongboonkerd V, Tuma Z, Moravec J, Matejovic M: Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis. Kidney Int 2009; 76: 404-413.
29. Ohi H, Sakamoto K, Hatano M: S protein (vitronectin) in hemodialysis patients. Nephron 1990; 54: 190-191.
30. Laine P, Pentikainen MO, Wurzner R, Penttila A, Paavonen T, Meri S, Kovanen PT: Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002; 90: 404-408.
31. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, van der Loos CM, Rittersma SZ, Chamuleau SA, Tijssen JG, Becker AE, Piek JJ: Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 2006; 59: 196-201.
32. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-1392.
33. Vlaicu R, Niculescu F, Rus HG, Cristea A: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57: 163-177.
34. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, Wagner O, Lang IM, Kubicek M: Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
35. Doran JP, Howie AJ, Townend JN, Bonser RS: Detection of myocardial infarction by immunohistological staining for C9 on formalin fixed, paraffin wax embedded sections. J Clin Pathol 1996; 49: 34-37.
36. Niculescu F, Rus HG, Vlaicu R: Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987; 45: 147-155.
37. Buerke M, Murohara T, Lefer AM: Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91: 393-402.
38. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC: Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268:H448-H457.
39. Riley RD, Sato H, Zhao ZQ, Thourani VH, Jordan JE, Fernandez AX, Ma XL, Hite DR, Rigel DF, Pellas TC, Peppard J, Bill KA, Lappe RW, Vinten-Johansen J: Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J Thorac Cardiovasc Surg 2000; 120: 350-358.
40. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
41. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
42. Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L: Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2011; 58: 479-486.
43. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A: Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47: 1500-1506.
44. Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13: 199-204.
45. The Renal Association: UK Renal Registry: The Seventeenth Annual Report, 2014.
46. Pertosa G, Grandaliano G, Valente M, Montinaro V, Soccio M, Gesualdo L, Schena FP: In vivo evaluation of biocompatibility of a new dialyzer employing the vitamin E-modified cellulose membrane 'Excebrane E': Study of mechanisms involved in mononuclear cell activation. Contrib Nephrol 1999; 127: 200-207.